Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 1 238 GBX 1.56% Market Closed
Market Cap: 1.5B GBX

Gross Margin
Indivior PLC

84%
Current
84%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
84%
=
Gross Profit
1.7B
/
Revenue
2.1B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
UK
Indivior PLC
LSE:INDV
1.5B GBP
84%
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
485.6B USD
68%
CH
Roche Holding AG
SIX:ROG
257.9B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP
82%
US
Merck & Co Inc
NYSE:MRK
265B USD
79%
CH
Novartis AG
SIX:NOVN
207.5B CHF
76%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
142.8B USD
75%
No Stocks Found

Indivior PLC
Glance View

Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.

INDV Intrinsic Value
4 092.68 GBX
Undervaluation 70%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
84%
=
Gross Profit
1.7B
/
Revenue
2.1B
What is the Gross Margin of Indivior PLC?

Based on Indivior PLC's most recent financial statements, the company has Gross Margin of 84%.

Back to Top